Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00217022 · ClinicalTrials.gov registry record · Phase 2
Budesonide Versus Placebo for the Treatment of Lymphocytic Colitis
A Phase 2 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT00217022: Clinical Trial Phase 2 study, sponsored by Mayo Clinic.
NCT00217022 is a Phase 2 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 16 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00217022, a Phase 2 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
Patients will receive budesonide or placebo for the treatment of active lymphocytic colitis. This study includes stool collections, blood draws, weekly questionnaires and a sigmoidoscopy. The study hypothesis is that budesonide will be safe and effective compared with placebo for the treatment of diarrhea in lymphocytic colitis.
Interventions
- OTHER Placebo
- DRUG Budesonide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2003-06 |
| Est. Completion | 2008-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00217022
The ClinicalTrials.gov registry entry for NCT00217022 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00217022 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00217022 about?
NCT00217022 is a clinical study titled "Budesonide Versus Placebo for the Treatment of Lymphocytic Colitis". Patients will receive budesonide or placebo for the treatment of active lymphocytic colitis. This study includes stool collections, blood draws, weekly questionnaires and a sigmoidoscopy. The study hypothesis is that budesonide will be safe and effective compared with placebo for the treatment of di...
What is the current status of trial NCT00217022?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2003-06. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00217022?
The interventions under investigation include: Placebo (OTHER), Budesonide (DRUG).
Who is sponsoring clinical trial NCT00217022?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.